肝动脉化疗栓塞与CD3AK细胞联合治疗中晚期肝癌的临床研究

目的：探讨肝动脉化疗栓塞与ＣＤ３ＡＫ细胞联合治疗中晚期肝癌的效果。方法：对３４例中晚期原发性肝癌采用经肝动脉化疗栓塞（ＴＡＣＥ）联合ＣＤ３ＡＫ细胞进行治疗（Ａ组）；同时对２７例相同患者单纯进行肝动脉化疗栓塞治疗（Ｂ组）。结果：①Ａ组部分缓解率为７６．５％（２６／３４），高于Ｂ组部分缓解率为５１．９％（１４／２７）（Ｐ〈０．０５）。Ａ组中位生存期为２２．３月，Ｂ组为１５．７月，两组相比有显著差异（Ｐ

Clinical study on the treatment of moderately advanced liver cancer with hepatic arterial chemoembolization and CD3AK cells

Objective:To evaluate the therapeutic results in treatment of moderately advanced primary liver cancer(PLC)with hepatic arterial chemoembolization(TACE)and CD3AK cellsMethods:34 patients of PLC were treated with TACE and CD3AK cells(group A)and 27 patients of those were treated with TACE alone(group B)Results:The rates of remission were 765% in Grop A and 519% in Group B(P<005)For group A,The median survival time,1,and 2year survival rate was 223 months,735% and 600%,respectively,which were higher than those of group B(157 months,487% and 320%)(P<001-005)The percentage of group A of T cell subsets CD+3CD+4 and CD+4/CD+8 radio increased and the sIL2R levels decreased after treatment,However,those of group B reverseConclusion:The results show the treatment of moderately advanced primary liver cancer with TACE and CD3AK cells can improve the therapeutic efficacy and the immune function of patients